Flibanserin: A controversial drug for female hypoactive sexual desire disorder | Zendy

Rakesh Agarwal | Zendy; Rashmi Baid | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Flibanserin: A controversial drug for female hypoactive sexual desire disorder

Author(s) -

Rakesh Agarwal,

Rashmi Baid

Publication year - 2018

Publication title -

industrial psychiatry journal

Language(s) - English

Resource type - Journals

eISSN - 0976-2795

pISSN - 0972-6748

DOI - 10.4103/ipj.ipj_20_16

Subject(s) - hypoactive sexual desire disorder , female sexual dysfunction , food and drug administration , sexual desire , sexual dysfunction , drug , psychology , libido , medicine , pharmacology , psychiatry , human sexuality , psychoanalysis , sociology , gender studies

Sexual functioning is an integral part of human life. Female sexual dysfunction (FSD) adversely affects quality of life and general well-being. The Food and Drug Administration recently approved flibanserin, for treatment of female hypoactive sexual desire disorder (HSDD), regarded as the most common FSD, amid great controversy. A novel multifunctional serotonin agonist and antagonist, flibanserin, has been shown to be efficacious in treating HSDD but with a rather tenacious side effect profile. We review this interesting drug in its entirety. Data for the article were collected by reviewing articles on PubMed, the drug (Addyi) website, and related websites on the internet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research